AboutContact us
dotsbydots
SEARCHCONTACT US

Buzz

Most popular

Daily
Weekly
1
Breaking down the resurgence of M&As in times of economic uncertainty
2
Quantum Art raises $100 million Series A to scale full-stack quantum systems
3
Dell in talks to acquire AI data-infrastructure startup Dataloop
4
Former Check co-founder, after $360M Intuit exit, launches Safebooks with $15M in Seed funding
5
A two-year-old Israeli unicorn is quietly stress-testing Amazon’s AI future
More news

Pharmaceuticals

20 stories about Pharmaceuticals
חברת ה תרופות טבע Teva

Fresh Teva Lawsuit Goes Against Dividends Paid by Debt Heavy Drugmaker

30.11.17|Anat Rouah
Tel Aviv-based capital investment firm Tulip Capital is threatening derivative action against Teva, saying the company's huge debt load renders its dividends unlawful
מנכ"ל טבע החדש קור שולץ

New CEO Steers Teva Back to Generics

28.11.17|Golan Hazani and Dror Reich
A reorganization plan announced by the company Monday would see the troubled drugmaker return to its core competencies, despite market pressures
default image

Biomed Company Protalix to Lay Off a Fifth of its Workforce

26.11.17|Dror Reich
The Israel-based NYSE American-listed company is currently undergoing a streamlining process
חממה של BOL קנאביס

Cannabis Breeder Barney's Farm Invests in Israeli Cannabis Company

23.11.17|Dror Reich
Barney's made a strategic investment of $2.1 million in Tel Aviv-listed Medivie Therapeutic Ltd., a company setting up a medical cannabis farm and pharmacy venture
default image

Perrigo Completes Sale of Israel Business for $110 million

23.11.17|Lilach Baumer
The buyer, New York-based investment firm SK Capital, has $1.9 billion assets under management
מנכ"ל טבע החדש קור שולץ 2

Troubled Drugmaker Teva to Axe over 4,000 Jobs

23.11.17|Golan Hazani
Less than a month after stepping in as CEO, Kåre Schultz starts tightening the belt. The company is expected to oust Chief Scientific Officer Michael Hayden
ראג'יב מאליק נשיא מיילן

Investors Cheer as Mylan Plans to Delist from Israeli Stock Exchange

12.11.17|Uri Tal-Tenne and Dror Reich
Mylan is currently the highest valued company on the TASE at $18.5 billion
תרופות טבע גלולות תרופה

Entera Bio Files for Nasdaq IPO

12.11.17|Lilach Baumer
The clinical stage company develops treatments mostly for osteoporosis and bone disorders
מטה טבע פתח תקווה

Fitch Downgrades Teva to Junk Rating

07.11.17|Yaniv Rahimi
The U.S. credit agency changed Teva's rating from BBB to BB, with a negative outlook, due to "significant operational stress." The downgrade might affect Teva's ability to take on additional debt
מפעל טבע נתניה

There May Be a Silver Lining to Teva’s Woes

06.11.17|Eli Shimony
Analysts have lowered their target price for Teva following the company's less than stellar third quarter reports, but the company can still turn its luck around with new drugs and a willingness to tighten the belt
מטה טבע פתח תקווה

Allergan Planning Sale of its Teva Stock

01.11.17|Dror Reich and Lilach Baumer
For the third quarter of 2017, Allergan reported an operating loss of $4.02 billion, $1.3 billion of which is due to the depreciation of its Teva securities.
מנכ"ל טבע החדש קור שולץ

New CEO to Take Helm at Troubled Teva Wednesday

31.10.17|Lilach Baumer
The generic drugmaker shed 67% of its market price over the last 12 months
מפעל חברת טבע הר חוצבים ירושלים

Teva's Blockbuster Drug Takes Another Generic Blow

26.10.17|Lilach Baumer
Mylan and European Partner Synthon won U.K. patent case related to Teva's Copaxone
מפעל חברת טבע הר חוצבים ירושלים

Teva Canada Probed by Ontario Government

23.10.17|Lilach Baumer
According to a report by Canadian newspaper Toronto Star the company is under investigation for alleged illegal rebates given to pharmacies to boost sales. A Teva spokesman said the company will cooperate fully with any investigation by the Ontario Ministry of Health.
מימין עודד ליברמן מנכל נוירודרם עם נציגי הרוכשת מיצובישי טנאבה

Mitsubishi Tanabe Pharma Finalizes $1.1 Billion Buy of Israel-Based NeuroDerm

19.10.17|Lilach Baumer
NeuroDerm is looking to bring major change to Parkinson patients with its drug reformulation
default image

Kite Pharma’s Cancer Drug Gets Regulatory Nod

19.10.17|Lilach Baumer
The cancer-treatment company, bought by Gilead Science in August for $11.9 billion, will sell one treatment course of the drug for $373,000
יצחק פטרבורג

Teva Submits Potential Moneymaker Migraine Drug for FDA Approval

18.10.17|Dror Reich and Lilach Baumer
Teva’s patent for its moneymaker multiple sclerosis drug Copaxone expired last year
default image

Lonza to Open Research and Development Center in Israel

10.10.17|Lilach Baumer
The company is looking to boost the research and development projects of its pharma and biotech division
אמיר וייסברג

Drug Conduction Company Prepares for Nasdaq IPO

08.10.17|Golan Hazani
Clinical stage PolyPid develops technology for the predetermined, controlled and localized release of drugs at a targeted site
חברת ה תרופות טבע Teva

Teva’s Stock Drops After Approval of Copaxone Competitors

08.10.17|Lilach Baumer
A day after Mylan announced FDA approval for its generic versions of Copaxone, drug companies Synthon and Alvogen announce European approval for their 40 mg/ml generic versions of Teva's blockbuster drug
Previous ArticlesMore Articles